For the quarter ending 2025-09-30, COLL made $209,361,000 in revenue. $31,507,000 in net income. Net profit margin of 15.05%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Product revenues, net | 209,361,000 | 188,000,000 | 177,757,000 | 163,436,000 |
| Intangible asset amortization and impairment | - | - | - | 41,326,000 |
| Cost of product revenues (excluding intangible asset amortization) | 24,717,000 | 24,143,000 | 24,960,000 | 27,238,000 |
| Intangible asset amortization and impairment | 55,473,000 | 55,473,000 | 55,473,000 | - |
| Total cost of product revenues | 80,190,000 | 79,616,000 | 80,433,000 | 68,564,000 |
| Gross profit | 129,171,000 | 108,384,000 | 97,324,000 | 94,872,000 |
| Selling, general and administrative | 67,103,000 | 73,637,000 | 76,423,000 | 52,536,500 |
| Gain on fair value remeasurement of contingent consideration | -19,000 | -358,000 | -786,000 | -728,500 |
| Total operating expenses | 67,084,000 | 73,279,000 | 75,637,000 | 51,079,500 |
| Income from operations | 62,087,000 | 35,105,000 | 21,687,000 | 43,792,500 |
| Interest expense | 21,767,000 | 20,463,000 | 20,790,000 | 19,996,500 |
| Loss on extinguishment of debt | - | - | - | 0 |
| Interest income | 3,116,000 | 2,383,000 | 2,225,000 | 3,149,500 |
| Income before income taxes | 43,436,000 | 17,025,000 | 3,122,000 | 26,945,500 |
| Provision for income taxes | 11,929,000 | 5,042,000 | 705,000 | 6,821,000 |
| Net income | 31,507,000 | 11,983,000 | 2,417,000 | 20,124,500 |
| Earnings per share, basic | 1 | 0.38 | 0.08 | 0.625 |
| Earnings per share, diluted | 0.84 | 0.34 | 0.07 | 0.535 |
| Weighted average number of shares outstanding, basic | 31,571,410 | 31,810,612 | 31,793,739 | -16,209,321.5 |
| Weighted average number of shares outstanding, diluted | 39,439,890 | 39,075,703 | 32,840,153 | -20,061,390 |
COLLEGIUM PHARMACEUTICAL, INC (COLL)
COLLEGIUM PHARMACEUTICAL, INC (COLL)